We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+9.51%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$28.5B
AUM Growth
+$2.42B
(+9.3%)
Cap. Flow
+$581M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
19.66%
Holding
1,921
New
171
Increased
1,320
Reduced
356
Closed
71
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$111M |
| 2 |
VF Corp
VFC
|
+$73.4M |
| 3 |
Amazon
AMZN
|
+$71M |
| 4 |
Stanley Black & Decker
SWK
|
+$60.2M |
| 5 |
Tesla
TSLA
|
+$46.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$158M |
| 2 |
Apple
AAPL
|
+$130M |
| 3 |
Cardinal Health
CAH
|
+$43.7M |
| 4 |
Fortinet
FTNT
|
+$39.6M |
| 5 |
ExxonMobil
XOM
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.73% |
| 2 | Industrials | 12.07% |
| 3 | Consumer Staples | 11.64% |
| 4 | Healthcare | 11.12% |
| 5 | Financials | 10.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Rocket Pharmaceuticals
RCKT
$348M
| $258K | ﹤0.01% |
13,174
+2,793
| +27% | +$51.4K |
|
1327
Urban Edge Properties
UE
$2.94B
| $256K | ﹤0.01% |
18,149
+2,337
| +15% | +$33.6K |
|
|
SILK
1328
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $255K | ﹤0.01% |
+4,828
| New | +$235K |
|
|
SWTX
1329
DELISTED
SpringWorks Therapeutics
SWTX
| $255K | ﹤0.01% |
9,794
+1,817
| +23% | +$44.8K |
|
1330
Ligand Pharmaceuticals
LGND
$6.02B
| $255K | ﹤0.01% |
3,811
-1,843
| -33% | -$120K |
|
1331
Methode Electronics
MEI
$543M
| $254K | ﹤0.01% |
+5,731
| New | +$245K |
|
1332
Replimune Group
REPL
$814M
| $254K | ﹤0.01% |
+9,341
| New | +$194K |
|
|
P
1333
Everpure Inc
P
$24.8B
| $253K | ﹤0.01% |
9,458
-980
| -9% | -$28.5K |
|
|
RNAM
1334
DELISTED
Avidity Biosciences
RNAM
| $253K | ﹤0.01% |
11,390
+1,358
| +14% | +$20.2K |
|
1335
DigitalOcean
DOCN
$14.4B
| $253K | ﹤0.01% |
9,920
+1,058
| +12% | +$33.1K |
|
|
VRTV
1336
DELISTED
VERITIV CORPORATION
VRTV
| $253K | ﹤0.01% |
+2,075
| New | +$251K |
|
|
CVSA
1337
Covista Inc
CVSA
$3.94B
| $252K | ﹤0.01% |
7,099
+922
| +15% | +$36K |
|
1338
MillerKnoll
MLKN
$1.5B
| $252K | ﹤0.01% |
11,984
-542
| -4% | -$10.8K |
|
|
MRTX
1339
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $251K | ﹤0.01% |
5,550
+75
| +1% | +$4.85K |
|
|
PR
1340
Permian Resources
PR
$17.9B
| $251K | ﹤0.01% |
26,752
+4,071
| +18% | +$39K |
|
1341
Recursion Pharmaceuticals
RXRX
$1.57B
| $251K | ﹤0.01% |
32,611
+3,707
| +13% | +$36.4K |
|
1342
MSC Industrial Direct
MSM
$7.02B
| $251K | ﹤0.01% |
+3,077
| New | +$251K |
|
1343
Kirby Corp
KEX
$7.95B
| $251K | ﹤0.01% |
3,902
+462
| +13% | +$30.8K |
|
1344
XPO
XPO
$25B
| $250K | ﹤0.01% |
7,500
-3,613
| -33% | -$122K |
|
1345
Verra Mobility
VRRM
$615M
| $250K | ﹤0.01% |
18,041
+2,244
| +14% | +$34.1K |
|
1346
Axalta
AXTA
$7.01B
| $249K | ﹤0.01% |
9,782
-190
| -2% | -$4.7K |
|
1347
Winnebago Industries
WGO
$870M
| $249K | ﹤0.01% |
4,726
+440
| +10% | +$25K |
|
1348
CEVA Inc
CEVA
$1.01B
| $248K | ﹤0.01% |
9,709
+1,010
| +12% | +$27.2K |
|
1349
Provident Financial Services
PFS
$3.11B
| $248K | ﹤0.01% |
11,605
+1,499
| +15% | +$32.2K |
|
1350
Agilysys
AGYS
$2.78B
| $247K | ﹤0.01% |
+3,127
| New | +$199K |
|
Similar funds
ProShare Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, ProShare Advisors held 1,921 positions worth $28.5B, up 9.3% from $26.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
ProShare Advisors's Q4 2022 filing shows 171 new, 1,320 increased, 356 reduced and 71 closed positions. Its largest new stake was Rivian: 689,839 shares worth $12.7M. The largest sale was Target, an estimated $158M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.
- ProShare Advisors's largest Q4 2022 buy was Rivian: 689,839 shares worth $12.7M.
- ProShare Advisors added most to Microsoft in Q4 2022, an estimated $111M increase.
- ProShare Advisors's biggest Q4 2022 reduction was Apple, cutting an estimated $130M.
- ProShare Advisors fully exited Target in Q4 2022, selling an estimated $158M.
- ProShare Advisors's ten largest holdings make up 20% of its $28.5B portfolio in Q4 2022.
- ProShare Advisors opened 171 new positions and closed 71 in Q4 2022.
- ProShare Advisors's portfolio value rose 9.3% quarter-over-quarter to $28.5B.
Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.